Procoralan (ivabradine)
Valdoxan (agomelatine)Please view below details of the selected news article.
|
Servier Announce £132/€185 Million Irish Manufacturing Investment and New Research Partnership
27/10/2006
London, 27 October 2006: Servier, the leading French independent research based pharmaceutical group and Mr Michael Martin, the Irish Enterprise, Trade and Employment Minister, today announced the creation of a new pharmaceutical manufacturing facility at Waterford and increased capacity at the existing facility in Arklow. This investment package, worth up to £132/€185 million, is expected to create around 200 new jobs over the next five to seven years.
At the same time, Servier announced the details of research partnerships between Servier and University College, Dublin across all their common fields of medical research.
Commenting on the new Irish investment package company founder and President Dr Jacques Servier said:
“Our many worldwide clients do not wish to depend on a single manufacturing facility and thus run a risk of lacking in medicinal products. The new manufacturing facility for active substances will be able to back up Bolbec in France if for any reason it could not manufacture some specialties. The marvellous administration and quite extraordinary success of the country have made it rise quickly up the ranks of European nations. I should also point out the quality of the Irish workforce which is talented, capable and loyal.”
The New Waterford Facility
From 2010 onwards, the Waterford facility will manufacture two new active substances resulting from Servier Research (Agomelatine and Terutroban), along with the active substances, Perindopril Arginine and Ivabradine. The cost of the first section of the Waterford project will amount to £32/€45 million. Thereafter, another production unit focusing on Strontium Ranelate is scheduled. The overall investment will amount to £78.5/€100-£82/€115 million over the next seven years with some 155 employees hired at the site.
Along with production, the Waterford site will also carry out some of the Group’s research and development activities, making it necessary to recruit highly qualified staff.
Servier Production in Arklow
Servier has also announced an increase in medication manufacturing capacity at its other Irish facility in Arklow. Fifteen pharmaceutical products are manufactured in Arklow for cardiovascular disease, diabetes and in the future, for depression. The extension should ensure overall production capacity of 140 million boxes from 2010 onwards. The projected cost of the extension programme amounts to £50/€70 million. Some 140 new staff are scheduled to be hired as part of the extension programme over the next 5 years, bringing the overall staff level to 350 people by 2010.
Servier Research Partnerships
In parallel with the two major industrial investment announcements in Ireland, Servier executives and the directors of University College Dublin (UCD) presented the details of the research partnerships between their teams in all medication research fields (molecular pathology, structural biology, formulation research, pharmacology, clinical research, biomathematics, bioinformatics, toxicology and proteomics).
The “Doctor Jacques Servier” Award
Servier executives also took the opportunity to officially award the “Doctor Jacques Servier” scholarship to the prize-winner, Dr. Marc Devocelle, at the French Embassy in Dublin on the 26th October, in the presence of the Ambassador of France in Ireland and the Ambassador of Ireland in France. The annual “Doctor Jacques Servier” scholarship was created at the initiative of the Servier Institute and the Ireland Fund of France, to promote scientific exchanges between the medical community, health industry, universities and research bodies in Ireland. Dr. Devocelle, of the Royal College of Surgeons in Ireland was awarded the prize for his work in the development of molecules for the prevention of cardiovascular disease (anti-thrombotics) and his research collaborations between Ireland and France.
Servier Worldwide
Servier is now present in 140 countries. 80% of Servier sales are international. In ten years, Servier turnover has increased by 200% to €2.8 billion in 2005. Also in 2005, Servier accounted for 23% of the French balance of trade in pharmaceutical products with 64% of its worldwide output manufactured in France. Servier exports from France have topped the €1 billion mark. Next month, Servier will inaugurate a new production facility in Gidy near to Orleans.
Servier Laboratories (United Kingdom) Ltd
Created in 1963, the UK was the first Servier subsidiary outside France. Now employing over 500 people in the UK, we recently moved our head office and research facilities to new state of the art premises in Wexham Springs, Buckinghamshire, at the heart of the UK pharmaceutical industry’s cluster in the Thames Valley. In 2005 Servier Laboratories had an annual turnover of close to £100 million and now ranks within the top 15 largest pharmaceutical companies in the UK. Servier Laboratories was the fastest growing pharmaceutical company in the UK in 2005 with a growth rate of 29 per cent against and industry average of around 6 per cent.
Servier Laboratories (Ireland) Ltd.
Established in 1974, with a total number of employees reaching now almost 60, Servier Laboratories (Ireland) Ltd. is the subsidiary of the Servier Group in Ireland, committed to providing medical information and programmes of continuous medical education to medical doctors, pharmacists and other healthcare professionals in Ireland. Servier is involved in the fields of cardiovascular diseases (hypertension, heart failure and coronary disease), diabetes and osteoporosis and is in the process of registering a drug for the treatment of depression.
Servier is currently ranked as the 20th largest pharmaceutical company and one of the fastest growing in Ireland. Today, almost 100,000 Irish patients benefit from one of Servier's innovative products every day. Most of these medicines are manufactured in Ireland.
The Servier Group has established a large number of research and medical education partnerships and sponsorships in Ireland such as:
- Servier Chair in Cardiovascular Pharmacology
- EFSD - Servier Research Grant (European Foundation for the Study of Diabetes)
- IOF - Servier Research Award (International Osteoporosis Foundation)
- ISHR - Servier Research Fellowship (International Society for Heart Research)
- Jean Delay International Prize in association with the (WPA) World Psychiatric Association.
The Servier Group has a long association with Ireland through its founder, Dr. Jacques Servier, who is an honorary fellow of the Royal College of Physicians in Ireland.
Contact:
For Servier UK media enquiries :
Contact: Roy Sutherwood on 0784 3305097
© 2007 LES LABORATOIRES SERVIER, an incorporated company of SERVIER. All Rights Reserved - Terms of Use
SERVIER does not sell its products over the Internet - More information
Last Updated 27/10/2006
Best viewed in Internet Explorer 6.0 or later, at 1024x768 resolution.
